Results 41 to 50 of about 101,408 (263)

The spectrum of triple-negative breast disease: high- and low-grade lesions

, 2017
Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape.
Reis-Filho, Jorge S., Schnitt, Stuart J., Britta Weigelt, Pareja, Fresia, Geyer, Felipe C., Weigelt, Britta, Rakha, Emad, Fresia Pareja, Stuart J. Schnitt, Jorge S. Reis-Filho, Ian O. Ellis, Felipe C. Geyer, Emad Rakha, Ellis, Ian O.   +13 more
core   +1 more source

Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)

, 2023
Primary breast neuroendocrine (NE) neoplasms are uncommon, and definitions harbor controversy. We retrospectively collected 73 triple‐negative breast cancers (TNBC) and evaluated NE biomarker expression along with p53 aberrant staining (which correlates ...
Sean M Hacking, Evgeny Yakirevich, Yihong Wang   +2 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Polyphenols as Promising Drugs against Main Breast Cancer Signatures

Antioxidants, 2017
Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular
María Losada-Echeberría, María Herranz-López, Vicente Micol, Enrique Barrajón-Catalán   +3 more
doaj   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Assessment of the Relationship of Treated Basal-Type Breast Cancer with Recurrence, Metastasis, and Chemotherapy Regimen at A Tertiary Hospital Over Five Years

Novelty in Biomedicine
Background: Some studies suggest that basal-type breast cancer is a subtype of triple-negative breast cancer, and some others mention that it is a unique type of breast cancer.
Mehran Sharifi Esfahani, Samaneh Ahmadi, Mahtab Taatii Moghadam   +2 more
doaj   +1 more source

ABC4 Consensus: First Latin American Meeting—Assessment, Comments, and Application of Its Recommendations

JCO Global Oncology, 2020
Breast cancer accounts for a high burden among all the neoplasms in Latin America, with more-advanced stages at presentation, which could result in high mortality rates.
Henry L. Gomez, Carlos Castañeda, Fernando Valencia, Rene Muñoz-Bermeo, Maria del Carmen Torrico, Silvia Neciosup   +5 more
doaj   +1 more source

Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer [PDF]

, 2020
Triple-negative breast carcinoma is a group of breast cancers that is known for aggressive and unpredictable clinical behavior affecting also younger women.
Vihervuori, Hilda
core  

False Negative Tests in Breast Cancer: A Case Report

, 2023
Background: Breast cancer is the most common cancer worldwide. An early and accurate diagnosis is essential in optimizing the disease outcome. Triple assessment which includes clinical assessment, imaging and pathological examination is recommended for ...
Lee, Yi Xuan
core   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source